<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="519db8a9-48ab-4826-a2b3-6d67d6a24017"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>These highlights do not include all the information needed to use WYMZYA Fe safely and effectively. See Full Prescribing Information for WYMZYA Fe.<br/>WYMZYA Fe [norethindrone and ethinyl estradiol tablets (chewable) and ferrous fumarate tablets] for oral use<br/>Initial U.S. Approval: 1975</title>
   <effectiveTime value="20250514"/>
   <setId root="4f824b11-14f3-4a92-a516-562b3a434df0"/>
   <versionNumber value="14"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="089153071" root="1.3.6.1.4.1.519.1"/>
            <name>Lupin Pharmaceuticals, Inc.</name>
            <assignedEntity>
               <assignedOrganization>
                  <id extension="675923163" root="1.3.6.1.4.1.519.1"/>
                  <name>LUPIN LIMITED</name>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="650582310" root="1.3.6.1.4.1.519.1"/>
                        <name>LUPIN LIMITED</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="68180-873" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="68180-832" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="68180-856" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84731" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PACK"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="68180-873" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84731" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PACK"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="68180-832" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84731" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PACK"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="68180-856" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="63230265-0714-4e50-99db-79750682821b"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL Product Data Elements Section"/>
               <effectiveTime value="20250514"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="68180-873" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>WYMZYA Fe
</name>
                        <formCode code="C47916" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="KIT"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>NORETHINDRONE AND ETHINYL ESTRADIOL</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <asContent>
                           <quantity>
                              <numerator value="1" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43168" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLISTER PACK"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="1" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code/>
                                    <formCode code="C43200" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="POUCH"/>
                                    <asContent>
                                       <quantity>
                                          <numerator value="3" unit="1"/>
                                          <denominator value="1"/>
                                       </quantity>
                                       <containerPackagedProduct>
                                          <code code="68180-873-73" codeSystem="2.16.840.1.113883.6.69"/>
                                          <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                       </containerPackagedProduct>
                                       <subjectOf>
                                          <marketingAct>
                                             <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                             <statusCode code="active"/>
                                             <effectiveTime>
                                                <low value="20201130"/>
                                             </effectiveTime>
                                          </marketingAct>
                                       </subjectOf>
                                    </asContent>
                                 </containerPackagedProduct>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <part>
                           <quantity>
                              <numerator value="21" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <partProduct>
                              <code code="68180-832" codeSystem="2.16.840.1.113883.6.69"/>
                              <name>WYMZYA Fe
</name>
                              <formCode code="C42893" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET, CHEWABLE"/>
                              <asEntityWithGeneric>
                                 <genericMedicine>
                                    <name> NORETHINDRONE AND ETHINYL ESTRADIOL </name>
                                 </genericMedicine>
                              </asEntityWithGeneric>
                              <ingredient classCode="ACTIB">
                                 <quantity>
                                    <numerator value="0.4" unit="mg"/>
                                    <denominator value="1" unit="1"/>
                                 </quantity>
                                 <ingredientSubstance>
                                    <code code="T18F433X4S" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>NORETHINDRONE</name>
                                    <activeMoiety>
                                       <activeMoiety>
                                          <code code="T18F433X4S" codeSystem="2.16.840.1.113883.4.9"/>
                                          <name>NORETHINDRONE</name>
                                       </activeMoiety>
                                    </activeMoiety>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="ACTIB">
                                 <quantity>
                                    <numerator value="0.035" unit="mg"/>
                                    <denominator value="1" unit="1"/>
                                 </quantity>
                                 <ingredientSubstance>
                                    <code code="423D2T571U" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>ETHINYL ESTRADIOL</name>
                                    <activeMoiety>
                                       <activeMoiety>
                                          <code code="423D2T571U" codeSystem="2.16.840.1.113883.4.9"/>
                                          <name>ETHINYL ESTRADIOL</name>
                                       </activeMoiety>
                                    </activeMoiety>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="H4N855PNZ1" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>.ALPHA.-TOCOPHEROL</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="3SY5LH9PMK" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>ANHYDROUS LACTOSE</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>CELLULOSE, MICROCRYSTALLINE</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>MAGNESIUM STEARATE</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="3OWL53L36A" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>MANNITOL</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="U725QWY32X" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>POVIDONE K30</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="5856J3G2A2" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>SODIUM STARCH GLYCOLATE TYPE A POTATO</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="96K6UQ3ZD4" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>SUCRALOSE</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="CHI530446X" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>VANILLIN</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <asContent>
                                 <quantity>
                                    <numerator value="21" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="68180-832-74" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43168" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLISTER PACK"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <characteristic classCode="OBS">
                                       <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                       <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CE"/>
                                    </characteristic>
                                 </subjectOf>
                              </asContent>
                           </partProduct>
                           <subjectOf>
                              <approval>
                                 <id extension="ANDA091332" root="2.16.840.1.113883.3.150"/>
                                 <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                                 <author>
                                    <territorialAuthority>
                                       <territory>
                                          <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                       </territory>
                                    </territorialAuthority>
                                 </author>
                              </approval>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20201130"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value xsi:type="CE" code="C48325" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="WHITE">
                                    <originalText>white to off white</originalText>
                                 </value>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value xsi:type="CE" code="C48348" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ROUND">
                                    <originalText>flat face beveled edge</originalText>
                                 </value>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value xsi:type="PQ" value="6" unit="mm"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value xsi:type="INT" value="1"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value xsi:type="ST">LU;M21</value>
                              </characteristic>
                           </subjectOf>
                           <consumedIn>
                              <substanceAdministration>
                                 <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                              </substanceAdministration>
                           </consumedIn>
                        </part>
                        <part>
                           <quantity>
                              <numerator value="7" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <partProduct>
                              <code code="68180-856" codeSystem="2.16.840.1.113883.6.69"/>
                              <name>WYMZYA Fe
</name>
                              <formCode code="C42998" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET"/>
                              <asEntityWithGeneric>
                                 <genericMedicine>
                                    <name> Ferrous fumarate </name>
                                 </genericMedicine>
                              </asEntityWithGeneric>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>CELLULOSE, MICROCRYSTALLINE</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="R5L488RY0Q" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>FERROUS FUMARATE</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>MAGNESIUM STEARATE</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="U725QWY32X" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>POVIDONE K30</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="5856J3G2A2" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>SODIUM STARCH GLYCOLATE TYPE A POTATO</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="C151H8M554" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>SUCROSE</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <asContent>
                                 <quantity>
                                    <numerator value="7" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="68180-856-74" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43168" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLISTER PACK"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <characteristic classCode="OBS">
                                       <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                       <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CE"/>
                                    </characteristic>
                                 </subjectOf>
                              </asContent>
                           </partProduct>
                           <subjectOf>
                              <approval>
                                 <id extension="ANDA091332" root="2.16.840.1.113883.3.150"/>
                                 <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                                 <author>
                                    <territorialAuthority>
                                       <territory>
                                          <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                       </territory>
                                    </territorialAuthority>
                                 </author>
                              </approval>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20201130"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value xsi:type="CE" code="C48332" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BROWN">
                                    <originalText>mottled</originalText>
                                 </value>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value xsi:type="CE" code="C48348" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ROUND">
                                    <originalText>flat face beveled edge</originalText>
                                 </value>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value xsi:type="PQ" value="6" unit="mm"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value xsi:type="INT" value="1"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value xsi:type="ST">LU;M22</value>
                              </characteristic>
                           </subjectOf>
                           <consumedIn>
                              <substanceAdministration>
                                 <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                              </substanceAdministration>
                           </consumedIn>
                        </part>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA091332" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20201130"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="ID915">
               <id root="5bd6388d-3100-4203-8006-29010e392ceb"/>
               <code code="43683-2" codeSystem="2.16.840.1.113883.6.1" displayName="RECENT MAJOR CHANGES SECTION"/>
               <title>RECENT MAJOR CHANGES</title>
               <effectiveTime value="20211217"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph ID="ID917">Warnings and Precautions (<linkHtml href="#ID768">5.11</linkHtml>)                                                            12/2021</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID706">
               <id root="5188d7c8-d8f8-49ea-9e5c-3179957de077"/>
               <code code="34066-1" codeSystem="2.16.840.1.113883.6.1" displayName="BOXED WARNING SECTION"/>
               <text>
                  <paragraph ID="ID707">
                     <content styleCode="bold">WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptive (COC) use. This risk increases with age, particularly in women over 35 years of age, and with the number of cigarettes smoked. For this reason, COCs are contraindicated in women who are over 35 years of age and smoke <content styleCode="italics">[see CONTRAINDICATIONS (<linkHtml href="#ID742">4</linkHtml>)]</content>.</content>
                  </paragraph>
               </text>
               <effectiveTime value="20211217"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph ID="ID709">
                           <content styleCode="bold">WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">See Full Prescribing Information for complete boxed warning.</content>
                           </content>
                        </paragraph>
                        <list listType="unordered" ID="ID710" styleCode="Disc">
                           <item>
                              <content styleCode="bold">WYMZYA Fe is contraindicated in women over 35 years old who smoke. (<linkHtml href="#ID742">4</linkHtml>)</content>
                           </item>
                           <item>
                              <content styleCode="bold">Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptives (COC) use. (<linkHtml href="#ID742">4</linkHtml>)</content>
                           </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID711">
               <id root="3d48e92f-92e3-4ccc-82e9-6a7949956330"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE</title>
               <text>
                  <paragraph ID="ID712">WYMZYA<content styleCode="bold">
                        <sup>TM</sup>
                     </content> Fe is indicated for use by females of reproductive potential to prevent pregnancy.</paragraph>
               </text>
               <effectiveTime value="20211217"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" ID="ID714" styleCode="Disc">
                           <item>WYMZYA Fe is a progestin/estrogen COC indicated for use by females of reproductive potential to prevent pregnancy. (<linkHtml href="#ID711">1</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID715">
               <id root="32913f1c-e197-421d-b960-49c1889300fa"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION</title>
               <effectiveTime value="20221229"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" ID="ID734" styleCode="Disc">
                           <item>Take one tablet by mouth at the same time every day. Tablets may be chewed or swallowed. (<linkHtml href="#ID716">2.1</linkHtml>)</item>
                           <item>Take tablets in the order directed on the blister .(<linkHtml href="#ID716">2.1</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID716">
                     <id root="86552b70-2604-4414-966c-39422e20946d"/>
                     <title>2.1 How to Start WYMZYA Fe</title>
                     <text>
                        <paragraph ID="ID717">WYMZYA Fe is dispensed in a blister <content styleCode="italics">[see HOW SUPPLIED/STORAGE AND HANDLING (<linkHtml href="#ID836">16</linkHtml>)].</content> WYMZYA Fe may be started using either a Day 1 start or a Sunday start (see Table 1). For the first cycle of a Sunday Start regimen, an additional method of contraception should be used until after the first 7 consecutive days of administration.</paragraph>
                     </text>
                     <effectiveTime value="20211217"/>
                  </section>
               </component>
               <component>
                  <section ID="ID718">
                     <id root="8b080b01-f72e-4960-8a38-4f2454594db5"/>
                     <title>2.2 How to Take WYMZYA Fe</title>
                     <text>
                        <paragraph ID="ID719">WYMZYA Fe (white active tablets and brown placebo tablets) may be swallowed whole or chewed and swallowed. If the tablet is chewed, the patient should drink a full glass (8 ounces) of liquid immediately after swallowing.</paragraph>
                        <table ID="ID720" width="0" styleCode="Noautorules">
                           <caption>  Table 1:   Instructions for Administration of WYMZYA Fe </caption>
                           <col width="319"/>
                           <col width="330"/>
                           <tbody>
                              <tr>
                                 <td valign="top" styleCode="Lrule Toprule Botrule Rrule" align="left">
                                    <content styleCode="bold"> Starting CHCs in women not currently using hormonal contraception (Day 1 Start or Sunday Start)</content>
                                    <br/>
                                    <br/>
                                    <content styleCode="bold"> Important:</content>
                                    <br/> Consider the possibility of ovulation and conception prior to initiation of this product.<br/>
                                    <br/>
                                    <content styleCode="bold"> Tablet Color:</content>
                                    <br/> ●   WYMZYA Fe active tablets are white (Day 1 to Day 21).<br/> ●  WYMZYA Fe placebo tablets are brown (Day 22 to Day 28).<br/>
                                 </td>
                                 <td valign="top" styleCode=" Toprule Botrule Rrule" align="left">
                                    <content styleCode="bold"> Day 1 Start:</content>
                                    <br/> ● Take first white active tablet on the first day of menses.<br/> ● Take subsequent white active tablets once daily at the same time each day for a total of 21 days.<br/> ● Take one <content styleCode="bold"> brown</content>  placebo tablet daily for 7 days and at the same time of day that active tablets were taken.<br/> ● Begin each subsequent pack on the same day of the week as the first cycle pack (i.e., on the day after taking the last inactive tablet).<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule"/>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left">
                                    <content styleCode="bold"> Sunday Start:</content>
                                    <br/> ● Take first active tablet on the first Sunday after the onset of menses. <content styleCode="bold"> Due to the potential risk of becoming pregnant, use additional non-hormonal contraception (such as condoms and spermicide) for the first seven days of the patient's first cycle pack of WYMZYA Fe</content> .<br/> ● Take subsequent <content styleCode="bold"> white</content>  active tablets once daily at the same time each day for a total of 21 days.<br/> ● Take one <content styleCode="bold"> brown</content>  placebo tablet daily for the following 7 days and at the same time of day that active tablets were taken.<br/> ●   Begin each subsequent pack on the same day of the week as the first cycle pack (i.e., on the Sunday after taking the last inactive tablet) and additional non-hormonal contraceptive is not needed.<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left">
                                    <content styleCode="bold"> Switching to WYMZYA Fe from another hormonal contraceptive</content>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> Start on the same day that a new pack of the previous hormonal contraceptive would have started.<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left">
                                    <content styleCode="bold"> Switching from another contraceptive method to WYMZYA Fe </content>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left">
                                    <content styleCode="bold"> Start WYMZYA Fe :</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left">
                                    <content styleCode="bold"> ● Transdermal patch</content>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> ● On the day when next application would have been scheduled<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left">
                                    <content styleCode="bold"> ● Vaginal ring</content>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> ●  On the day when next insertion would have been scheduled<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left">
                                    <content styleCode="bold"> ● Injection</content>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> ●  On the day when next injection would have been scheduled<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left">
                                    <content styleCode="bold"> ●  Intrauterine contraceptive</content>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> ●  On the day of removal<br/> ● If the IUD is not removed on first day of the patient's menstrual cycle, additional non-hormonal contraceptive (such as condoms and spermicide) is needed for the first seven days of the first cycle pack.<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left">
                                    <content styleCode="bold"> ●  Implant</content>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> ●  On the day of removal<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="2" valign="top" styleCode="Lrule Botrule Rrule" align="left">
                                    <content styleCode="bold"> Complete instructions to facilitate patient counseling on proper tablet usage are located in the FDA-Approved Patient Labeling.</content>
                                    <br/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph ID="ID721">
                           <content styleCode="bold">
                              <content styleCode="italics">Starting WYMZYA Fe after Abortion or Miscarriage</content>
                           </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">First-trimester:</content>
                           </content>
                        </paragraph>
                        <list listType="unordered" ID="ID722" styleCode="Disc">
                           <item>After a first-trimester abortion or miscarriage, WYMZYA Fe may be      started immediately. An additional method of contraception is not needed      if WYMZYA Fe is started within 5 days after termination of the pregnancy.</item>
                           <item>If WYMZYA Fe is not started within 5 days after termination of the      pregnancy, the patient should use additional non-hormonal contraception      (such as condoms and spermicide) for the first seven days of her first      cycle pack of WYMZYA Fe.</item>
                        </list>
                        <paragraph ID="ID723">
                           <content styleCode="bold">
                              <content styleCode="italics">Second-trimester:</content>
                           </content>
                        </paragraph>
                        <list listType="unordered" ID="ID724" styleCode="Disc">
                           <item>Do not start until 4 weeks after a second-trimester abortion or      miscarriage, due to the increased risk of thromboembolic disease. Start      WYMZYA Fe, following the instructions in Table 1 for Day 1 or Sunday      start, as desired. If using Sunday start, use additional non- hormonal      contraception (such as condoms and spermicide) for the first seven days of      the patient's first cycle pack of WYMZYA Fe. <content styleCode="italics">[see CONTRAINDICATIONS      (<linkHtml href="#ID742">4</linkHtml>), WARNINGS AND PRECAUTIONS (<linkHtml href="#ID748">5.1</linkHtml>),      and FDA-APPROVED PATIENT LABELING.]</content>
                           </item>
                        </list>
                        <paragraph ID="ID725">
                           <content styleCode="bold">
                              <content styleCode="italics">Starting WYMZYA Fe after Childbirth</content>
                           </content>
                        </paragraph>
                        <list listType="unordered" ID="ID726" styleCode="Disc">
                           <item>Do not start until 4 weeks after delivery, due to the increased risk      of thromboembolic disease. Start contraceptive therapy with WYMZYA Fe      following the instructions in Table 1 for women not currently using      hormonal contraception.</item>
                           <item>If the woman has not yet had a period postpartum, consider the      possibility of ovulation and conception occurring prior to use of WYMZYA      Fe. <content styleCode="italics">[see CONTRAINDICATIONS (<linkHtml href="#ID742">4</linkHtml>), WARNINGS AND      PRECAUTIONS (<linkHtml href="#ID748">5.1</linkHtml>), USE IN SPECIFIC POPULATIONS (<linkHtml href="#ID798">8.1      </linkHtml>and <linkHtml href="#ID800">8.3</linkHtml>), and FDA-APPROVED      PATIENT LABELING]</content> .</item>
                        </list>
                     </text>
                     <effectiveTime value="20221229"/>
                  </section>
               </component>
               <component>
                  <section ID="ID729">
                     <id root="33ef0b7c-abc5-452b-a5b1-26bb2f48cb23"/>
                     <title>2.3 Missed Tablets</title>
                     <text>
                        <table ID="ID914" width="590" styleCode="Noautorules">
                           <caption>  Table 2:   Instructions for Missed WYMZYA Fe Tablets </caption>
                           <col width="295"/>
                           <col width="295"/>
                           <tbody>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> ●   If one white active tablet is missed in Weeks 1, 2, or 3<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> Take the tablet as soon as possible. Continue taking one tablet a day until the pack is finished.<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> ●   If two white active tablets are missed in Week 1 or Week 2<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> Take the two missed tablets as soon as possible and the next two active tablets the next day. Continue taking one tablet a day until the pack is finished. <content styleCode="bold"> Additional non-hormonal contraception (such as condoms and spermicide) should be used as back-up if the patient has sex within 7 days after missing tablets.</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> ●  If two white active tablets are missed in Week 3 or three or more white active tablets are missed in a row in Weeks 1, 2, or 3<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left">
                                    <content styleCode="bold">
                                       <content styleCode="underline">Day 1 start</content>
                                    </content> : Throw out the rest of the pack and start a new pack that same day.<br/>
                                    <content styleCode="bold">
                                       <content styleCode="underline">Sunday start</content>
                                    </content> : Continue taking one tablet a day until Sunday, then throw out the rest of the pack and start a new pack that same day.<br/>
                                    <content styleCode="bold"> Additional non-hormonal contraception (such as condoms and spermicide) should be used as back-up if the patient has sex within 7 days after missing tablets.</content>
                                    <br/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20221229"/>
                  </section>
               </component>
               <component>
                  <section ID="ID731">
                     <id root="426a532f-d296-44c3-a577-80fef0c04ce0"/>
                     <title>2.4 Advice in Case of Gastrointestinal Disturbances</title>
                     <text>
                        <paragraph ID="ID732">In case of severe vomiting or diarrhea, absorption may not be complete and additional contraceptive measures should be taken. If vomiting or diarrhea occurs within 3 to 4 hours after taking an active tablet, handle this as a missed tablet <content styleCode="italics">[see FDA-APPROVED PATIENT LABELING]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20201127"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID735">
               <id root="22a8ad43-f6d7-4cd5-9f78-63c274153f2d"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS</title>
               <text>
                  <paragraph ID="ID736">WYMZYA Fe [norethindrone and ethinyl estradiol tablets USP (chewable) and ferrous fumarate tablets] is available in blister.</paragraph>
                  <paragraph>Each blister contains 28 tablets in the following order:</paragraph>
                  <list listType="unordered" ID="ID738" styleCode="Disc">
                     <item>21 white to off-white, round (active), flat face, beveled edge      tablets debossed with "LU" on one side and "M21" on the other      side and each containing 0.4 mg norethindrone and 35 mcg ethinyl      estradiol.</item>
                     <item>7 brown, mottled, round (non-hormonal placebo), flat face, beveled      edge tablets debossed with "LU" on one side and "M22" on the      other side and each containing 75 mg ferrous fumarate. The ferrous      fumarate tablets do not serve any therapeutic purpose.</item>
                  </list>
               </text>
               <effectiveTime value="20211217"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph ID="ID740">WYMZYA Fe consists of 28 tablets in the following order (<linkHtml href="#ID735">3</linkHtml>):</paragraph>
                        <list listType="unordered" ID="ID741" styleCode="Disc">
                           <item>21 white tablets (active), each containing 0.4 mg norethindrone and 35 mcg ethinyl estradiol</item>
                           <item>7 brown tablets (non-hormonal placebo), each containing 75 mg ferrous fumarate. The ferrous fumarate tablets do not serve any therapeutic purpose.</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID742">
               <id root="d1c1cd4b-6636-460f-b667-e4b327b2d550"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS</title>
               <text>
                  <paragraph ID="ID743">WYMZYA Fe is contraindicated in females who are known to have or develop the following conditions:</paragraph>
                  <list listType="unordered" ID="ID930" styleCode="Disc">
                     <item>A high risk of      arterial or venous thrombotic diseases. Examples include women who are      known to:<list listType="unordered" styleCode="Circle">
                           <item>Smoke, if over      age 35 <content styleCode="italics">[see BOXED WARNING and WARNINGS AND PRECAUTIONS      (<linkHtml href="#ID748">5.1</linkHtml>)]</content>
                           </item>
                           <item>Have deep vein      thrombosis or pulmonary embolism, now or in the past <content styleCode="italics">[see WARNINGS AND      PRECAUTIONS (<linkHtml href="#ID748">5.1</linkHtml>)]</content>
                           </item>
                           <item>Have inherited      or acquired hypercoagulopathies <content styleCode="italics">[see WARNINGS AND PRECAUTIONS      (<linkHtml href="#ID748">5.1</linkHtml>)]</content>
                           </item>
                           <item>Have      cerebrovascular disease <content styleCode="italics">[see WARNINGS AND PRECAUTIONS      (<linkHtml href="#ID748">5.1</linkHtml>)]</content>
                           </item>
                           <item>Have coronary      artery disease <content styleCode="italics">[see WARNINGS AND PRECAUTIONS      (<linkHtml href="#ID748">5.1</linkHtml>)]</content>
                           </item>
                           <item>Have      thrombogenic valvular or thrombogenic rhythm diseases of the heart (for      example, subacute bacterial endocarditis with valvular disease, or atrial      fibrillation) <content styleCode="italics">[see WARNINGS AND PRECAUTIONS (<linkHtml href="#ID748">5.1</linkHtml>)]</content>
                           </item>
                           <item>Have      uncontrolled hypertension <content styleCode="italics">[see WARNINGS AND PRECAUTIONS      (<linkHtml href="#ID754">5.4</linkHtml>)]</content>
                           </item>
                           <item>Have diabetes      mellitus with vascular disease <content styleCode="italics">[see WARNINGS AND PRECAUTIONS      (<linkHtml href="#ID758">5.6</linkHtml>)]</content>
                           </item>
                           <item>Have headaches      with focal neurological symptoms or have migraine headaches with aura <content styleCode="italics">[see      WARNINGS AND PRECAUTIONS (<linkHtml href="#ID760">5.7</linkHtml>)]</content>
                           </item>
                        </list>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20230511"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" ID="ID746" styleCode="Disc">
                           <item>A high risk of arterial or venous thrombotic diseases (<linkHtml href="#ID742">4</linkHtml>)</item>
                           <item>Liver tumors or liver disease (<linkHtml href="#ID742">4</linkHtml>)</item>
                           <item>Undiagnosed abnormal uterine bleeding (<linkHtml href="#ID742">4</linkHtml>)</item>
                           <item>Pregnancy (<linkHtml href="#ID742">4</linkHtml>)</item>
                           <item>Current diagnosis of, or history of, breast cancer, which may be hormone-sensitive  (<linkHtml href="#ID742">4</linkHtml>)</item>
                           <item>Co-administration with Hepatitis C drug combinations containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir (<linkHtml href="#ID742">4</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID747">
               <id root="c0d01978-9887-42e4-9641-b68189cc2191"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS</title>
               <effectiveTime value="20230511"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" ID="ID779" styleCode="Disc">
                           <item>
                              <content styleCode="underline">Thrombotic Disorders and Other Vascular Problems:</content> Stop WYMZYA Fe if a thrombotic event occurs. Stop at least 4 weeks before through 2 weeks after major surgery. Start no earlier than 4 weeks after delivery, in women who are not breastfeeding (<linkHtml href="#ID748">5.1</linkHtml>)</item>
                           <item>
                              <content styleCode="underline">Liver disease</content> : Discontinue WYMZYA Fe if jaundice occurs (<linkHtml href="#ID752">5.2</linkHtml>)</item>
                           <item>
                              <content styleCode="underline">High blood pressure</content> : If used in women with well-controlled hypertension, monitor blood pressure and stop WYMZYA Fe if blood pressure rises significantly. (<linkHtml href="#ID755">5.4</linkHtml>)</item>
                           <item>
                              <content styleCode="underline">Carbohydrate and lipid metabolic effects</content> : Monitor prediabetic and diabetic women taking WYMZYA Fe. Consider an alternative contraceptive method for women with uncontrolled dyslipidemia (<linkHtml href="#ID759">5.6</linkHtml>)</item>
                           <item>
                              <content styleCode="underline">Headache</content> : Evaluate significant change in headaches and discontinue WYMZYA Fe if indicated <linkHtml href="#ID761">(5.7</linkHtml>)</item>
                           <item>
                              <content styleCode="underline">Bleeding Irregularities and Amenorrhea</content> : Evaluate irregular bleeding or amenorrhea (<linkHtml href="#ID763">5.8</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID748">
                     <id root="2151868b-c0b2-4e85-b68d-fe6dc8020202"/>
                     <title>5.1 Thrombotic Disorders and Other Vascular Problems</title>
                     <text>
                        <list listType="unordered" ID="ID749" styleCode="Disc">
                           <item>Stop WYMZYA Fe if an arterial thrombotic event or venous      thromboembolic (VTE) event occurs.</item>
                           <item>Stop WYMZYA Fe if there is unexplained loss of vision, proptosis,      diplopia, papilledema, or retinal vascular lesions. Evaluate for retinal      vein thrombosis immediately.</item>
                           <item>If feasible, stop WYMZYA Fe at least 4 weeks before and through 2      weeks after major surgery or other surgeries known to have an elevated      risk of VTE as well as during the following prolonged immobilization.</item>
                           <item>Start WYMZYA Fe no earlier than 4 weeks after delivery, in women who      are not breastfeeding. The risk of postpartum VTE decreases after the      third postpartum week, whereas the risk of ovulation increases after the      third postpartum week.</item>
                           <item>The use of COCs increases the risk of VTE. However, pregnancy increases      the risk of VTE as much or more than the use of COCs. The risk of VTE in      women using COCs is 3 to 9 per 10,000 woman-years. The risk of VTE is      highest during the first year of use of COCs and when restarting hormonal      contraception after a break of 4 weeks or longer. The risk of      thromboembolic disease due to COCs gradually disappears after use is      discontinued.</item>
                           <item>Use of COCs also increases the risk of arterial thromboses such as      strokes and myocardial infarctions, especially in women with other risk      factors for these events. COCs have been shown to increase both the      relative and attributable risks of cerebrovascular events (thrombotic and      hemorrhagic strokes). The risk increases with age, particularly in women      over 35 years of age who smoke.</item>
                           <item>Use COCs with caution in women with cardiovascular disease risk      factors.</item>
                        </list>
                     </text>
                     <effectiveTime value="20211217"/>
                  </section>
               </component>
               <component>
                  <section ID="ID752">
                     <id root="98193767-4b92-4ee5-b208-542beea6c8d3"/>
                     <title>5.2 Liver Disease</title>
                     <text>
                        <paragraph ID="ID753">
                           <content styleCode="bold">
                              <content styleCode="italics">Impaired Liver Function</content>
                           </content>
                        </paragraph>
                        <paragraph>Do not use WYMZYA Fe in women with liver disease, such as acute viral hepatitis or severe (decompensated) cirrhosis of liver <content styleCode="italics">[see CONTRAINDICATIONS (<linkHtml href="#ID742">4</linkHtml>)]</content>. Acute or chronic disturbances of liver function may necessitate the discontinuation of COC use until markers of liver function return to normal and COC causation has been excluded. Discontinue WYMZYA Fe if jaundice develops.</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Liver Tumors</content>
                           </content>
                        </paragraph>
                        <paragraph>WYMZYA Fe is contraindicated in women with benign and malignant liver tumors <content styleCode="italics">[see CONTRAINDICATIONS (<linkHtml href="#ID742">4</linkHtml>)]</content>. Hepatic adenomas are associated with COC use. An estimate of the attributable risk is 3.3 cases/100,000 COC users. Rupture of hepatic adenomas may cause death through intra-abdominal hemorrhage.</paragraph>
                        <paragraph>Studies have shown an increased risk of developing hepatocellular carcinoma in long-term (&gt;8 years) COC users. However, the risk of liver cancers in COC users is less than one case per million users.  </paragraph>
                     </text>
                     <effectiveTime value="20211217"/>
                  </section>
               </component>
               <component>
                  <section ID="ID918">
                     <id root="fd32bf56-d038-4f39-8537-8487b1bf5c20"/>
                     <title>5.3 Risk of Liver Enzyme Elevations with Concomitant Hepatitis C Treatment</title>
                     <text>
                        <paragraph ID="ID919">During clinical trials with the Hepatitis C combination drug regimen that contains ombitasvir/paritaprevir/ritonavir, with or without dasabuvir, ALT elevations greater than 5 times the upper limit of normal (ULN),including some cases greater than 20 times the ULN, were significantly more frequent in women using ethinyl estradiol-containing medications, such as COCs. Discontinue WYMZYA Fe prior to starting therapy with the combination drug regimen ombitasvir/paritaprevir/ritonavir, with or without dasabuvir [<content styleCode="italics">see CONTRAINDICATIONS (<linkHtml href="#ID745">4</linkHtml>)</content>].</paragraph>
                        <paragraph>WYMZYA Fe can be restarted approximately 2 weeks following completion of treatment with the Hepatitis C combination drug regimen. </paragraph>
                     </text>
                     <effectiveTime value="20211217"/>
                  </section>
               </component>
               <component>
                  <section ID="ID754">
                     <id root="9eae96b5-8c69-43a3-b07b-0e732980acc9"/>
                     <title>5.4 High Blood Pressure</title>
                     <text>
                        <paragraph ID="ID755">WYMZYA Fe is contraindicated in women with uncontrolled hypertension or hypertension with vascular disease <content styleCode="italics">[see CONTRAINDICATIONS (<linkHtml href="#ID742">4</linkHtml>)]</content>. For women with well-controlled hypertension, monitor blood pressure and stop WYMZYA Fe if blood pressure rises significantly.</paragraph>
                        <paragraph>An increase in blood pressure has been reported in women taking COCs, and this increase is more likely in older women with extended duration of use. The incidence of hypertension increases with increasing concentrations of progestin.</paragraph>
                     </text>
                     <effectiveTime value="20201127"/>
                  </section>
               </component>
               <component>
                  <section ID="ID756">
                     <id root="4b57ea6e-3243-40e4-9a93-57c4d80028ab"/>
                     <title>5.5 Gallbladder Disease</title>
                     <text>
                        <paragraph ID="ID757">Studies suggest a small increased relative risk of developing gallbladder disease among COC users. Use of COCs may worsen existing gallbladder disease. A past history of COC-related cholestasis predicts an increased risk with subsequent COC use. Women with a history of pregnancy-related cholestasis may be at an increased risk for COC related cholestasis.</paragraph>
                     </text>
                     <effectiveTime value="20201127"/>
                  </section>
               </component>
               <component>
                  <section ID="ID758">
                     <id root="360dae80-3b5b-465c-a3e2-1c0ce71360c5"/>
                     <title>5.6 Carbohydrate and Lipid Metabolic Effects</title>
                     <text>
                        <paragraph ID="ID759">Carefully monitor prediabetic and diabetic women who take WYMZYA Fe. COCs may decrease glucose tolerance.</paragraph>
                        <paragraph>Consider alternative contraception for women with uncontrolled dyslipidemia. A small proportion of women will have adverse lipid changes while on COCs.</paragraph>
                        <paragraph>Women with hypertriglyceridemia, or a family history thereof, may be at an increased risk of pancreatitis when using COCs.</paragraph>
                     </text>
                     <effectiveTime value="20201127"/>
                  </section>
               </component>
               <component>
                  <section ID="ID760">
                     <id root="1825b163-f2ca-4b43-b905-f306edadc343"/>
                     <title>5.7 Headache</title>
                     <text>
                        <paragraph ID="ID761">If a woman taking WYMZYA Fe develops new headaches that are recurrent, persistent, or severe, evaluate the cause and discontinue WYMZYA Fe if indicated.</paragraph>
                        <paragraph>Consider discontinuation of WYMZYA Fe in the case of increased frequency or severity of migraine during COC use (which may be prodromal of a cerebrovascular event).</paragraph>
                     </text>
                     <effectiveTime value="20201127"/>
                  </section>
               </component>
               <component>
                  <section ID="ID762">
                     <id root="bc6fc82c-285a-44d6-827c-99f26bded6e9"/>
                     <title>5.8 Bleeding Irregularities and Amenorrhea</title>
                     <text>
                        <paragraph ID="ID763">
                           <content styleCode="bold">
                              <content styleCode="italics">Unscheduled Bleeding and Spotting</content>
                           </content>
                        </paragraph>
                        <paragraph>Unscheduled (breakthrough or intracyclic) bleeding and spotting sometimes occur in patients on COCs, especially during the first three months of use. If bleeding persists or occurs after previously regular cycles, check for causes such as pregnancy or malignancy. If pathology and pregnancy are excluded, bleeding irregularities may resolve over time or with a change to a different contraceptive product.</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Amenorrhea and Oligomenorrhea</content>
                           </content>
                        </paragraph>
                        <paragraph>Women who use WYMZYA Fe may experience amenorrhea. Some women may experience amenorrhea or oligomenorrhea after discontinuation of COCs, especially when such a condition was preexistent.</paragraph>
                        <paragraph>If scheduled (withdrawal) bleeding does not occur, consider the possibility of pregnancy. If the patient has not adhered to the prescribed dosing schedule (missed one or more active tablets or started taking them on a day later than she should have), consider the possibility of pregnancy at the time of the first missed period and take appropriate diagnostic measures. If the patient has adhered to the prescribed regimen and misses two consecutive periods, rule out pregnancy.</paragraph>
                     </text>
                     <effectiveTime value="20201127"/>
                  </section>
               </component>
               <component>
                  <section ID="ID764">
                     <id root="2379cfc1-1290-472d-9859-3a43184fca05"/>
                     <title>5.9 COC Use Before or During Early Pregnancy</title>
                     <text>
                        <paragraph ID="ID765">Extensive epidemiologic studies have revealed no increased risk of birth defects in women who have used oral contraceptives prior to pregnancy. Studies also do not suggest a teratogenic effect, particularly in so far as cardiac anomalies and limb reduction defects are concerned, when oral contraceptives are taken inadvertently during early pregnancy. Discontinue WYMZYA Fe use if pregnancy is confirmed.</paragraph>
                        <paragraph>Administration of COCs to induce withdrawal bleeding should not be used as a test for pregnancy <content styleCode="italics">[see USE IN SPECIFIC POPULATIONS (<linkHtml href="#ID798">8.1</linkHtml>)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20201127"/>
                  </section>
               </component>
               <component>
                  <section ID="ID766">
                     <id root="75b685ce-2ec5-4f34-9087-35a2c355df7a"/>
                     <title>5.10 Depression</title>
                     <text>
                        <paragraph ID="ID767">Carefully observe women with a history of depression and discontinue WYMZYA Fe if depression recurs to a serious degree.</paragraph>
                     </text>
                     <effectiveTime value="20201127"/>
                  </section>
               </component>
               <component>
                  <section ID="ID768">
                     <id root="be959a83-2c6d-4715-98b8-67af21485c07"/>
                     <title>
                        <content styleCode="xmChange">5.11 Malignant Neoplasms</content>
                     </title>
                     <text>
                        <paragraph ID="ID922">
                           <content styleCode="xmChange">
                              <content styleCode="italics">Breast Cancer</content>
                              <br/>
                              <br/>
WYMZYA Fe is contraindicated in females who currently have or have had breast cancer because breast cancer may be hormonally sensitive <content styleCode="italics">[see </content>
                              <content styleCode="italics">CONTRAINDICATIONS (<linkHtml href="#ID742">4</linkHtml>)]</content>.<br/>
                              <br/>
Epidemiology studies have not found a consistent association between use of combined oral contraceptives (COCs) and breast cancer risk. Studies do not show an association between ever (current or past) use of COCs and risk of breast cancer. However, some studies report a small increase in the risk of breast cancer among current or recent users (&lt;6 months since last use) and current users with longer duration of COC use <content styleCode="italics">[see POSTMARKETING EXPERIENCE (<linkHtml href="#ID923">6.2</linkHtml>)]</content>.<br/>
                              <br/>
                              <content styleCode="italics">Cervical Cancer</content>
                              <br/>
                              <br/>
Some studies suggest that COC use has been associated with an increase in the risk of cervical cancer or intraepithelial neoplasia. However, there continues to be controversy about the extent to which such findings may be due to differences in sexual behavior and other factors.<br/>
                           </content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20230511"/>
                  </section>
               </component>
               <component>
                  <section ID="ID770">
                     <id root="5c53bc94-1d2b-4103-9045-6859984df6b3"/>
                     <title>5.12 Effect on Binding Globulins</title>
                     <text>
                        <paragraph ID="ID771">The estrogen component of COCs may raise the serum concentrations of thyroxine-binding globulin, sec hormone-binding globulin, and cortisol-binding globulin. The dose of replacement thyroid hormone or cortisol therapy may need to be increased.</paragraph>
                     </text>
                     <effectiveTime value="20201127"/>
                  </section>
               </component>
               <component>
                  <section ID="ID772">
                     <id root="00aa4110-4fd0-4f02-bb4b-dbb7937e379a"/>
                     <title>5.13 Monitoring</title>
                     <text>
                        <paragraph ID="ID773">A woman who is taking COCs should have a yearly visit with her healthcare provider for a blood pressure check and for other indicated healthcare.</paragraph>
                     </text>
                     <effectiveTime value="20201127"/>
                  </section>
               </component>
               <component>
                  <section ID="ID774">
                     <id root="75c811c4-e620-42f3-9ae3-0daa6c8f1374"/>
                     <title>5.14 Hereditary Angioedema</title>
                     <text>
                        <paragraph ID="ID775">In women with hereditary angioedema, exogenous estrogens may induce or exacerbate symptoms of angioedema.</paragraph>
                     </text>
                     <effectiveTime value="20201127"/>
                  </section>
               </component>
               <component>
                  <section ID="ID776">
                     <id root="a716e6e7-2179-4567-8240-d987bab1f738"/>
                     <title>5.15 Chloasma</title>
                     <text>
                        <paragraph ID="ID777">Chloasma may occasionally occur, especially in women with a history of chloasma gravidarum. Women with a tendency to chloasma should avoid exposure to the sun or ultraviolet radiation while taking WYMZYA Fe.</paragraph>
                     </text>
                     <effectiveTime value="20201127"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID780">
               <id root="a1dcf6b3-50ea-4d41-b4b4-6525d09e4001"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS</title>
               <effectiveTime value="20250514"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph ID="ID786">The most common adverse reactions were: irregular uterine bleeding, nausea, breast tenderness, and headache. (<linkHtml href="#ID780">6</linkHtml>)</paragraph>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Lupin Pharmaceuticals, Inc. at 1-800-399-2561 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID923">
                     <id root="ffef6d8a-5747-417f-b629-8637e7263ed5"/>
                     <title>6.2 Postmarketing Experience</title>
                     <text>
                        <paragraph ID="ID924">Five studies that compared breast cancer risk between ever-users (current or past use) of COCs and never-users of COCs reported no association between ever use of COCs and breast cancer risk, with effect estimates ranging from 0.90 - 1.12 (Figure 1).</paragraph>
                        <paragraph>Three studies compared breast cancer risk between current or recent COC users (&lt;6 months since last use) and never users of COCs (Figure 1). One of these studies reported no association between breast cancer risk and COC use. The other two studies found an increased relative risk of 1.19 - 1.33 with current or recent use. Both of these studies found an increased risk of breast cancer with current use of longer duration, with relative risks ranging from 1.03 with less than one year of COC use to approximately 1.4 with more than 8-10 years of COC use.</paragraph>
                        <renderMultiMedia referencedObject="MM1">
                           <caption>Figure 1: Risk of Breast Cancer with Combined Oral Contraceptive Use</caption>
                        </renderMultiMedia>
                        <paragraph ID="ID926">RR = relative risk; OR = odds ratio; HR = hazard ratio. "ever COC" are females with current or past COC use; "never COC use" are females that never used COCs.</paragraph>
                        <paragraph>The following serious adverse reactions with the use of COCs are discussed elsewhere in the labeling:</paragraph>
                        <list listType="unordered" ID="ID927" styleCode="Disc">
                           <item>Serious cardiovascular events and stroke <content styleCode="italics">[see BOXED WARNING and WARNINGS AND PRECAUTIONS (5.1)]</content>
                           </item>
                           <item>Vascular events <content styleCode="italics">[see WARNINGS AND PRECAUTIONS (5.1)]</content>
                           </item>
                           <item>Liver disease <content styleCode="italics">[see WARNINGS AND PRECAUTIONS (5.2)]</content>
                           </item>
                        </list>
                        <paragraph ID="ID928">The following adverse reactions are commonly reported by COC users. Because these reactions are voluntarily reported by from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure:</paragraph>
                        <list listType="unordered" ID="ID929" styleCode="Disc">
                           <item>Irregular uterine bleeding</item>
                           <item>Nausea</item>
                           <item>Breast tenderness</item>
                           <item>Headache</item>
                        </list>
                     </text>
                     <effectiveTime value="20250514"/>
                  </section>
               </component>
               <component>
                  <observationMedia ID="MM1">
                     <text>Figure 1: Risk of Breast Cancer with Combined Oral Contraceptive Use</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="519db8a9-48ab-4826-a2b3-6d67d6a24017-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID787">
               <id root="b0fdc624-293c-4c99-9bdd-b82b1bd46173"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>7 DRUG INTERACTIONS</title>
               <text>
                  <paragraph ID="ID788">Consult the labeling of concurrently used drugs to obtain further information about interactions with hormonal contraceptives or the potential for enzyme alterations.</paragraph>
               </text>
               <effectiveTime value="20211217"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" ID="ID796" styleCode="Disc">
                           <item>Drugs or herbal products that induce certain enzymes, including CYP3A4, may decrease the effectiveness of COCs or increase breakthrough bleeding. Counsel patients to use a back-up method or alternative method of contraception when enzyme inducers are used with COCs (<linkHtml href="#ID789">7.1</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID789">
                     <id root="1086a896-1666-422c-a9cf-751e00ffd6b8"/>
                     <title>7.1 Effects of Other Drugs on Combined Oral Contraceptives</title>
                     <text>
                        <paragraph ID="ID790">
                           <content styleCode="bold">
                              <content styleCode="italics">Substances Decreasing the Plasma Concentrations of COCs and Potentially Diminishing the Efficacy of COCs</content>
                           </content>
                        </paragraph>
                        <paragraph>Drugs or herbal products that induce certain enzymes, including cytochrome P450 3A4 (CYP3A4), may decrease the plasma concentrations of COCs and potentially diminish the effectiveness of COCs or increase breakthrough bleeding. Some drugs or herbal products that may decrease the effectiveness of hormonal contraceptives include phenytoin, barbiturates, carbamazepine, bosentan, felbamate, griseofulvin, oxcarbazepine, rifampicin, topiramate, rifabutin, rufinamide, aprepitant, and products containing St. John's wort. Interactions between hormonal contraceptives and other drugs may lead to breakthrough bleeding and/or contraceptive failure. Counsel women to use an alternative method of contraception or a back-up method when enzyme inducers are used with COCs, and to continue back-up contraception for 28 days after discontinuing the enzyme inducer to ensure contraceptive reliability.</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Colesevelam</content>
                           </content>
                        </paragraph>
                        <paragraph>Colesevelam, a bile acid sequestrant, given together with a COC, has been shown to significantly decrease the AUC of EE. The drug interaction between the contraceptive and colesevelam was decreased when the two drug products were given 4 hours apart.</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Substances Increasing the Plasma Concentrations of COCs</content>
                           </content>
                        </paragraph>
                        <paragraph>Co-administration of atorvastatin or rosuvastatin and certain COCs containing EE increase AUC values for EE by approximately 20 to 25%. Ascorbic acid and acetaminophen may increase plasma EE concentrations, possibly by inhibition of conjugation. CYP3A4 inhibitors, such as itraconazole, fluconazole, grapefruit juice, or ketoconazole may increase plasma hormone concentrations.</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Human Immunodeficiency Virus (HIV)/Hepatitis C Virus (HCV) Protease Inhibitors and Non- nucleoside Reverse Transcriptase Inhibitors</content>
                           </content>
                        </paragraph>
                        <paragraph>Significant changes (increase or decrease) in the plasma concentrations of estrogen and/or progestin have been noted in some cases of co-administration with HIV protease inhibitors (decrease [e.g., nelfinavir, ritonavir, darunavir/ritonavir, (fos)amprenavir/ritonavir, lopinavir/ritonavir, and tipranavir/ritonavir] or increase [e.g., indinavir and atazanavir/ritonavir])/HCV protease inhibitors (decrease [e.g., nevirapine] or increase [e.g., etravirine]).</paragraph>
                     </text>
                     <effectiveTime value="20211217"/>
                  </section>
               </component>
               <component>
                  <section ID="ID791">
                     <id root="f2e5480f-8772-47ab-a4d6-e9ea0633dc3d"/>
                     <title>7.2 Effects of Combined Oral Contraceptives on Other Drugs</title>
                     <text>
                        <paragraph ID="ID792">COCs containing EE may inhibit the metabolism of other compounds (e.g., cyclosporine prednisolone, theophylline, tizanidine, and voriconazole) and increase their plasma concentrations. COCs have been shown to decrease plasma concentrations of acetaminophen, clofibric acid, morphine, salicylic acid, temazepam and lamotrigine. Significant decrease in plasma concentration of lamotrigine has been shown, likely due to induction of lamotrigine glucuronidation. This may reduce seizure control; therefore, dosage adjustments of lamotrigine may be necessary.</paragraph>
                        <paragraph>Women on thyroid hormone replacement therapy may need increased doses of thyroid hormone because the serum concentration of thyroid-binding globulin increases with use of COCs <content styleCode="italics">[see WARNINGS AND PRECAUTIONS (<linkHtml href="#ID770">5.12</linkHtml>)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20211208"/>
                  </section>
               </component>
               <component>
                  <section ID="ID920">
                     <id root="82a2330f-9526-453f-855f-aa331372a312"/>
                     <title>7.3 Concomitant Use with HCV Combination Therapy – Liver Enzyme Elevation</title>
                     <text>
                        <paragraph ID="ID921">Do not co-administer WYMZYA Fe with HCV drug combinations containing ombitasvir/ paritaprevir/ritonavir, with or without dasabuvir, due to potential for ALT elevations [<content styleCode="italics">see</content> <content styleCode="italics">WARNINGS AND PRECAUTIONS (<linkHtml href="#ID918">5.3</linkHtml>)</content>]. </paragraph>
                     </text>
                     <effectiveTime value="20211217"/>
                  </section>
               </component>
               <component>
                  <section ID="ID793">
                     <id root="1ff286ba-5476-41cb-8389-e5eab5b77384"/>
                     <title>7.4 Interference with Laboratory Tests</title>
                     <text>
                        <paragraph ID="ID794">The use of contraceptive steroids may influence the results of certain laboratory tests, such as coagulation factors, lipids, glucose tolerance, and binding proteins.</paragraph>
                     </text>
                     <effectiveTime value="20201127"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID797">
               <id root="928700cd-afd2-424d-b1d1-f17b920759a8"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS</title>
               <effectiveTime value="20211217"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" ID="ID812" styleCode="Disc">
                           <item>Nursing mothers: Advise use of another contraceptive method.</item>
                        </list>
                        <paragraph ID="ID813">WYMZYA Fe can decrease milk production. (<linkHtml href="#ID800">8.3</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID798">
                     <id root="b5d0f889-5db0-4dc4-afc5-5b3540f2cc2a"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy</title>
                     <text>
                        <paragraph ID="ID799">There is little or no increased risk of birth defects in women who inadvertently use COCs during early pregnancy. Epidemiologic studies and meta-analyses have not found an increased risk of genital or non-genital birth defects (including cardiac anomalies and limb reduction defects) following exposure to low dose COCs prior to conception or during early pregnancy.</paragraph>
                        <paragraph>Do not use COCs to induce withdrawal bleeding as a test for pregnancy. Do not use COCs during pregnancy to treat threatened or habitual abortion. </paragraph>
                     </text>
                     <effectiveTime value="20211217"/>
                  </section>
               </component>
               <component>
                  <section ID="ID800">
                     <id root="bcc87dd9-f362-421b-bcda-d1b057b5dfe3"/>
                     <code code="34080-2" codeSystem="2.16.840.1.113883.6.1" displayName="NURSING MOTHERS SECTION"/>
                     <title>8.3 Nursing Mothers</title>
                     <text>
                        <paragraph ID="ID801">Advise the nursing mother to use other forms of contraception, when possible, until she has weaned her child. COCs can reduce milk production in breastfeeding mothers. This is less likely to occur once breastfeeding is well-established; however, it can occur at any time in some women. Small amounts of oral contraceptive steroids and/or metabolites are present in breast milk.</paragraph>
                     </text>
                     <effectiveTime value="20211217"/>
                  </section>
               </component>
               <component>
                  <section ID="ID802">
                     <id root="2cd178bb-b553-48b7-8fc9-af08f8b5dac9"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use</title>
                     <text>
                        <paragraph ID="ID803">Safety and efficacy of WYMZYA Fe have been established in women of reproductive age. Efficacy is expected to be the same in post-pubertal adolescents under the age of 18 years as for users 18 years and older. Use of this product before menarche is not indicated.</paragraph>
                     </text>
                     <effectiveTime value="20211208"/>
                  </section>
               </component>
               <component>
                  <section ID="ID805">
                     <id root="26631cb2-1734-4a27-80f7-c525fd233236"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5 Geriatric Use</title>
                     <text>
                        <paragraph ID="ID806">WYMZYA Fe has not been studied in postmenopausal women and is not indicated in this population.</paragraph>
                     </text>
                     <effectiveTime value="20201127"/>
                  </section>
               </component>
               <component>
                  <section ID="ID807">
                     <id root="c9265b3c-a35d-4ce0-8e3e-1b0da2cb2b58"/>
                     <title>8.6 Hepatic Impairment</title>
                     <text>
                        <paragraph ID="ID808">The pharmacokinetics of WYMZYA Fe has not been studied in women with hepatic impairment. However, steroid hormones may be poorly metabolized in patients with hepatic impairment. Acute or chronic disturbances of liver function may necessitate the discontinuation of COC use until markers of liver function return to normal and COC causation has been excluded <content styleCode="italics">[see CONTRAINDICATIONS (<linkHtml href="#ID742">4</linkHtml>) and WARNINGS AND PRECAUTIONS (<linkHtml href="#ID752">5.2</linkHtml>)].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20201127"/>
                  </section>
               </component>
               <component>
                  <section ID="ID809">
                     <id root="50dac6dc-5356-4027-b735-6b7ec58e53a4"/>
                     <title>8.7 Renal Impairment</title>
                     <text>
                        <paragraph ID="ID810">The pharmacokinetics of WYMZYA Fe has not been studied in women with renal impairment.</paragraph>
                     </text>
                     <effectiveTime value="20201127"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID814">
               <id root="5df75b9f-e30f-4523-a424-182f2c6f2cd6"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>10 OVERDOSAGE</title>
               <text>
                  <paragraph ID="ID815">There have been no reports of serious ill effects from overdosage of oral contraceptives, including ingestion by children. Overdosage may cause withdrawal bleeding in females and nausea.</paragraph>
               </text>
               <effectiveTime value="20201127"/>
            </section>
         </component>
         <component>
            <section ID="ID816">
               <id root="78caa428-6c9e-4980-8038-5f61a0645287"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION</title>
               <text>
                  <paragraph ID="ID817">WYMZYA Fe is a combinational contraceptive containing the progestational compound norethindrone and the estrogenic compound ethinyl estradiol. The packaging includes 21 white tablets composed of norethindrone and ethinyl estradiol followed by 7 brown ferrous fumarate (placebo) tablets. The chemical name for norethindrone is 17-hydroxy-19-nor-17α-pregn-4-en-20-yn-3-one and for ethinyl estradiol the chemical name is 19-nor-17α-pregna-1,3,5(10)-trien-20-yne-3,17-diol. The structural formulas are:</paragraph>
                  <renderMultiMedia referencedObject="MM2"/>
                  <paragraph ID="ID819">The active white WYMZYA Fe tablets contain 0.4 mg norethindrone and 0.035 mg ethinyl estradiol, and the following inactive ingredients: lactose anhydrous, magnesium stearate, mannitol, microcrystalline cellulose, povidone, sodium starch glycolate, sucralose, vanillin and vitamin E.</paragraph>
                  <paragraph>The brown tablets contain ferrous fumarate, magnesium stearate, microcrystalline cellulose, povidone, sodium starch glycolate and sucrose. The ferrous fumarate tablets do not serve any therapeutic purpose.</paragraph>
                  <paragraph>FDA approved dissolution test specifications differ from USP.</paragraph>
               </text>
               <effectiveTime value="20250514"/>
               <component>
                  <observationMedia ID="MM2">
                     <text>image-1</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="519db8a9-48ab-4826-a2b3-6d67d6a24017-02.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID820">
               <id root="9042cbc1-cc60-4d44-9788-5d58b061501e"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY</title>
               <effectiveTime value="20211217"/>
               <component>
                  <section ID="ID821">
                     <id root="3c5fb278-0bc3-4181-bcf9-52b3cd4db4e0"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action</title>
                     <text>
                        <paragraph ID="ID822">COCs lower the risk of becoming pregnant primarily by suppressing ovulation. Other possible mechanisms may include cervical mucus changes that inhibit sperm penetration and endometrial changes that reduce the likelihood of implantation.    </paragraph>
                     </text>
                     <effectiveTime value="20211217"/>
                  </section>
               </component>
               <component>
                  <section ID="ID823">
                     <id root="530a1a6d-7d8a-47ad-9c85-aad10d22bab8"/>
                     <code code="43681-6" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>12.2 Pharmacodynamics</title>
                     <text>
                        <paragraph ID="ID824">No specific pharmacodynamic studies were conducted with WYMZYA Fe.</paragraph>
                     </text>
                     <effectiveTime value="20211217"/>
                  </section>
               </component>
               <component>
                  <section ID="ID825">
                     <id root="5e4e485d-2fa9-4031-8824-08e93364d921"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics</title>
                     <text>
                        <paragraph ID="ID826">
                           <content styleCode="bold">
                              <content styleCode="italics">Absorption</content>
                           </content>
                        </paragraph>
                        <paragraph>Ethinyl estradiol and norethindrone are rapidly absorbed with maximum plasma concentrations occurring within 2 hours after WYMZYA Fe administration (see Table 1). Norethindrone appears to be completely absorbed following oral administration; however, it is subject to first-pass metabolism resulting in an absolute bioavailability of approximately 65 percent. Large intersubject variability is reflected in a 3- to 5-fold variation in norethindrone bioavailability. Ethinyl estradiol bioavailability is approximately 43 percent due to small-intestinal and hepatic first-pass metabolism. </paragraph>
                        <table ID="ID827" width="100%">
                           <caption>Table 3.Mean ±SD Pharmacokinetic Parameters Following Single Dose Administration of WYMZYA Fe in Healthy Female Subjects Under Fasting Conditions.</caption>
                           <col width="25%"/>
                           <col width="18%"/>
                           <col width="19%"/>
                           <col width="20%"/>
                           <col width="18%"/>
                           <tbody>
                              <tr>
                                 <td align="left" valign="top" styleCode=" Lrule Rrule Botrule Toprule">Norethindrone/Ethinyl Estradiol<br/>
                                 </td>
                                 <td align="left" valign="top" styleCode=" Lrule Rrule Botrule Toprule">t<sub>m</sub>
                                    <sub>a</sub>
                                    <sub>x</sub> (h)<br/>
                                 </td>
                                 <td align="left" valign="top" styleCode=" Lrule Rrule Botrule Toprule">C<sub>m</sub>
                                    <sub>a</sub>
                                    <sub>x</sub> (pg/mL)<br/>
                                 </td>
                                 <td align="left" valign="top" styleCode=" Lrule Rrule Botrule Toprule">AUC<sub>0</sub>
                                    <sub> </sub>
                                    <sub>t</sub>
                                    <sub>o</sub>
                                    <sub> </sub>
                                    <sub>∞</sub>
                                    <br/>(pg•h/mL)<br/>
                                 </td>
                                 <td align="left" valign="top" styleCode=" Lrule Rrule Botrule Toprule">t<sub>1</sub>
                                    <sub>/</sub>
                                    <sub>2</sub>
                                    <sub> </sub>(h)<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode=" Lrule Rrule Botrule Toprule">Norethindrone 0.4 mg<br/>
                                 </td>
                                 <td align="left" valign="top" styleCode=" Lrule Rrule Botrule Toprule">1.24 ± 0.40<footnote ID="ID827_1">n = 26</footnote>
                                    <br/>
                                 </td>
                                 <td align="left" valign="top" styleCode=" Lrule Rrule Botrule Toprule">4210.6 ± 1628.8<footnoteRef IDREF="ID827_1"/>
                                    <br/>
                                 </td>
                                 <td align="left" valign="top" styleCode=" Lrule Rrule Botrule Toprule">18034.9 ± 7852.9<footnote ID="ID827_3">n = 25</footnote>
                                    <br/>
                                 </td>
                                 <td align="left" valign="top" styleCode=" Lrule Rrule Botrule Toprule">8.6 ± 3.7<footnoteRef IDREF="ID827_3"/>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode=" Lrule Rrule Botrule Toprule">Ethinyl Estradiol 35 mcg<br/>
                                 </td>
                                 <td align="left" valign="top" styleCode=" Lrule Rrule Botrule Toprule">1.44 ± 0.33<footnoteRef IDREF="ID827_3"/>
                                    <br/>
                                 </td>
                                 <td align="left" valign="top" styleCode=" Lrule Rrule Botrule Toprule">131.4 ± 34.2<footnoteRef IDREF="ID827_3"/>
                                    <br/>
                                 </td>
                                 <td align="left" valign="top" styleCode=" Lrule Rrule Botrule Toprule">1065.8 ± 276.2<footnoteRef IDREF="ID827_3"/>
                                    <br/>
                                 </td>
                                 <td align="left" valign="top" styleCode=" Lrule Rrule Botrule Toprule">17.1 ± 4.4<footnoteRef IDREF="ID827_3"/>
                                    <br/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph ID="ID828">C<sub>max</sub> = maximum plasma concentration; t<sub>max</sub> = time to reach C<sub>max</sub>; AUC = area under the curve;</paragraph>
                        <paragraph>t<sub>1/2</sub> = elimination half- life.</paragraph>
                        <paragraph ID="ID829">
                           <content styleCode="bold">
                              <content styleCode="italics">Food Effect:</content>
                           </content>
                        </paragraph>
                        <paragraph>Single-dose administration of WYMZYA Fe tablets with food decreased the maximum norethindrone and ethinyl estradiol concentration by 53 percent and 47 percent, respectively; the extent of norethindrone and ethinyl estradiol absorption (AUC values) was not affected by food administration.</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Distribution</content>
                           </content>
                        </paragraph>
                        <paragraph>Norethindrone is 36 percent bound to sex hormone-binding globulin (SHBG) and 61 percent bound to albumin. Ethinyl estradiol is not bound to SHBG but is highly (98.5 percent) bound to albumin. Volume of distribution of norethindrone and ethinyl estradiol ranges from 2 to 4 L/kg.</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Metabolism</content>
                           </content>
                        </paragraph>
                        <paragraph>Norethindrone undergoes extensive biotransformation, primarily via reduction, followed by sulfate and glucuronide conjugation; less than 5 percent of a norethindrone dose is excreted unchanged; greater than 50 percent and 20 to 40 percent of a dose is excreted in urine and feces, respectively. The majority of metabolites in the circulation are sulfates, with glucuronides accounting for most of the urinary metabolites.</paragraph>
                        <paragraph>Ethinyl estradiol is also extensively metabolized, both by oxidation and by conjugation with sulfate and glucuronide. Sulfates are the major circulating conjugates of ethinyl estradiol, and glucuronides predominate in urine. The primary oxidative metabolite is 2-hydroxy-ethinyl estradiol, which is formed by the CYP3A4 isoform of cytochrome P450.</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Excretion</content>
                           </content>
                        </paragraph>
                        <paragraph>Plasma clearance values for norethindrone and ethinyl estradiol are similar (approximately 0.4 L/hr/kg). Ethinyl estradiol and norethindrone are excreted in both urine and feces, primarily as metabolites. Ethinyl estradiol is excreted in urine and feces as glucuronides and sulfates, and about 28 to 43 percent undergoes enterohepatic circulation. The mean terminal elimination half- lives of norethindrone and ethinyl estradiol following single dose administration of WYMZYA Fe are approximately 9 hours and 17 hours, respectively.</paragraph>
                     </text>
                     <effectiveTime value="20211217"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID830">
               <id root="0e2f39ff-52ac-48fa-b7e3-6f5110934301"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY</title>
               <effectiveTime value="20211217"/>
               <component>
                  <section ID="ID831">
                     <id root="d358502b-5da0-42f2-82a0-e43926a917c4"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <text>
                        <paragraph ID="ID832">
                           <content styleCode="italics">[See WARNINGS AND PRECAUTIONS (<linkHtml href="#ID768">5.11</linkHtml>) and USE IN SPECIFIC POPULATIONS (<linkHtml href="#ID798">8.1</linkHtml>)]. </content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20211217"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID833">
               <id root="e65b141f-24fe-4267-b68d-0c7c71b62feb"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>14 CLINICAL STUDIES</title>
               <text>
                  <paragraph ID="ID834">The data presented in Section 14 are from a clinical trial conducted with norethindrone   0.4 mg/ethinyl estradiol 35 mcg tablets. WYMZYA Fe is bioequivalent to these norethindrone acetate/ethinyl estradiol tablets.</paragraph>
                  <paragraph>In a multicenter open-label clinical trial, 1,970 women, 98% of whom were 16 to 39 years of age, were studied for up to 31 cycles (28 days per cycle) to assess the efficacy of norethindrone /ethinyl estradiol tablets, completing the equivalent of 20,230 cycles of exposure. The racial demographic of all enrolled women was: Caucasian (56%), African-American (14%), and Other (30%) (Hispanic, Native American, etc.). Of treated women, 10% were lost to follow-up, 11% discontinued related to cycle control and 7% discontinued due to other adverse events</paragraph>
                  <paragraph>The pregnancy rate (Pearl Index [PI]) in all 1,970 women was 1.48 pregnancies per 100 women- years of use (95% confidence interval 0.94 –2.22), based on 23 pregnancies that occurred after the onset of treatment of norethindrone /ethinyl estradiol tablets.</paragraph>
               </text>
               <effectiveTime value="20201127"/>
            </section>
         </component>
         <component>
            <section ID="ID836">
               <id root="7c8189df-28fe-42a3-beda-2a7978ab7768"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING</title>
               <effectiveTime value="20211217"/>
               <component>
                  <section ID="ID839">
                     <id root="3a6ab2e7-a08a-4e7c-8213-151f700b1864"/>
                     <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
                     <title>16.1 How Supplied</title>
                     <text>
                        <paragraph ID="ID837">WYMZYA Fe [norethindrone and ethinyl estradiol tablets USP (chewable) and ferrous fumarate tablets] is available in a blister pack (NDC 68180-873-71) containing 28 tablets packed in a pouch (NDC 68180-873-71). Such three pouches are packaged in a carton (NDC 68180-873-73).</paragraph>
                        <paragraph>Each blister contains 28 tablets in the following order:</paragraph>
                        <list listType="unordered" ID="ID840" styleCode="Disc">
                           <item>21 white to off-white, round (active), flat face, beveled edge      tablets debossed with "LU" on one side and "M21" on the other      side and each containing 0.4 mg norethindrone and 35 mcg ethinyl      estradiol.</item>
                           <item>7 brown, mottled, round (non-hormonal placebo), flat face, beveled      edge tablets debossed with "LU" on one side and "M22" on the      other side and each containing 75 mg ferrous fumarate.</item>
                        </list>
                     </text>
                     <effectiveTime value="20211217"/>
                  </section>
               </component>
               <component>
                  <section ID="ID841">
                     <id root="71e10f83-78d0-41c2-a3ad-8c0301c9f67a"/>
                     <title>16.2 Storage Conditions</title>
                     <text>
                        <list listType="unordered" ID="ID842" styleCode="Disc">
                           <item>Store at 25°C (77°F); excursions permitted to 15 to 30°C (59 to 86°F) [see USP Controlled Room Temperature].</item>
                           <item>Keep this and all medications out of the reach of children.</item>
                        </list>
                     </text>
                     <effectiveTime value="20211217"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID843">
               <id root="6670204a-7641-4006-977f-b621113faa5c"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION</title>
               <text>
                  <paragraph ID="ID844">See FDA-Approved Patient Labeling (Patient Information and Instructions for Use)</paragraph>
                  <paragraph>Counsel patients about the following information:</paragraph>
                  <list listType="unordered" ID="ID845" styleCode="Disc">
                     <item>Cigarette smoking increases the risk of serious cardiovascular      events from COC use, and that women who are over 35 years old and smoke      should not use COCs <content styleCode="italics">[see BOXED WARNING].</content>
                     </item>
                     <item>Increased risk of VTE compared to non-users of COCs is greatest      after initially starting a COC or restarting (following a 4-week or      greater pill-free interval) the same or a different COC <content styleCode="italics">[see WARNINGS      AND PRECAUTIONS (<linkHtml href="#ID748">5.1</linkHtml>)]</content> .</item>
                     <item>WYMZYA Fe does not protect against HIV infection (AIDS) and other      sexually transmitted diseases.</item>
                     <item>WYMZYA Fe is not to be used during pregnancy; if pregnancy occurs      during use of WYMZYA Fe, instruct the patient to stop further use <content styleCode="italics">[see      WARNINGS AND PRECAUTIONS (<linkHtml href="#ID764">5.9</linkHtml>)].</content>
                     </item>
                     <item>Take one tablet daily by mouth at the same time every day. Instruct      patients what to do in the event pills are missed <content styleCode="italics">[see DOSAGE AND      ADMINISTRATION (<linkHtml href="#ID729">2.3</linkHtml>)].</content>
                     </item>
                     <item>Use a back-up or alternative method of contraception when enzyme      inducers are used with WYMZYA Fe <content styleCode="italics">[see DRUG INTERACTIONS (<linkHtml href="#ID789">7.1</linkHtml>)].</content>
                     </item>
                     <item>COCs may reduce breast milk production; this is less likely to occur      if breastfeeding is well established <content styleCode="italics">[see USE IN SPECIFIC POPULATIONS (<linkHtml href="#ID800">8.3</linkHtml>)].</content>
                     </item>
                     <item>A woman who starts COCs postpartum and who has not yet had a period      should use an additional method of contraception until she has taken a      white tablet for 7 consecutive days <content styleCode="italics">[see DOSAGE AND ADMINISTRATION (<linkHtml href="#ID718">2.2</linkHtml>)].</content>
                     </item>
                     <item>Amenorrhea may occur. Consider pregnancy in the event of amenorrhea      at the time of the first missed period. Rule out pregnancy in the event of      amenorrhea in two or more consecutive cycles <content styleCode="italics">[see WARNINGS AND      PRECAUTIONS (<linkHtml href="#ID762">5.8</linkHtml>)].</content>
                     </item>
                  </list>
                  <renderMultiMedia referencedObject="MM3"/>
                  <paragraph ID="ID846">Distributed by:</paragraph>
                  <paragraph>
                     <content styleCode="bold">Lupin Pharmaceuticals, Inc.</content>
                  </paragraph>
                  <paragraph>Naples, FL 34108</paragraph>
                  <paragraph>United States</paragraph>
                  <paragraph>Manufactured by:</paragraph>
                  <paragraph>
                     <content styleCode="bold">Lupin Limited</content>
                  </paragraph>
                  <paragraph>Pithampur (M.P.) - 454 775</paragraph>
                  <paragraph>India</paragraph>
                  <paragraph>Revised: November 2024</paragraph>
               </text>
               <effectiveTime value="20250514"/>
               <component>
                  <observationMedia ID="MM3">
                     <text>image</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="519db8a9-48ab-4826-a2b3-6d67d6a24017-03.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID847">
               <id root="7846b680-5aa8-4356-8e44-618aaaf60ca1"/>
               <code code="42230-3" codeSystem="2.16.840.1.113883.6.1" displayName="SPL PATIENT PACKAGE INSERT SECTION"/>
               <text>
                  <paragraph ID="ID848">
                     <content styleCode="bold">Patient Information</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">WYMZYA<sup>TM</sup> Fe</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">[WYM-zee-yah EFF-EE]</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">[norethindrone and ethinyl estradiol tablets (chewable) and ferrous fumarate tablets]</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">What is the most important information I should know about WYMZYA Fe?</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Do not use WYMZYA Fe if you smoke cigarettes and are over 35 years old.</content> Smoking increases your risk of serious cardiovascular side effects (heart and blood vessel problems) from birth control pills, including death from heart attack, blood clots or stroke. This risk increases with age and the number of cigarettes you smoke.</paragraph>
                  <paragraph>
                     <content styleCode="bold">What is WYMZYA Fe?</content>
                  </paragraph>
                  <paragraph>WYMZYA Fe is a birth control pill (oral contraceptive) used by women to prevent pregnancy.</paragraph>
                  <paragraph>
                     <content styleCode="bold">How does WYMZYA Fe work for contraception?</content>
                  </paragraph>
                  <paragraph>Your chance of getting pregnant depends on how well you follow the directions for taking your birth control pills. The better you follow the directions, the less chance you have of getting pregnant.</paragraph>
                  <paragraph>Based on the results of one clinical study of a 28-day regimen of norethindrone 0.4 mg/ethinyl estradiol 35 mcg tablets, about 1 to 2 out of 100 women may get pregnant during the first year they use WYMZYA Fe.</paragraph>
                  <paragraph>The following chart shows the chance of getting pregnant for women who use different methods of birth control. Each box on the chart contains a list of birth control methods that are similar in effectiveness. The most effective methods are at the top of the chart. The box on the bottom of the chart shows the chance of getting pregnant for women who do not use birth control and are trying to get pregnant.</paragraph>
                  <renderMultiMedia referencedObject="MM4"/>
                  <paragraph ID="ID850">
                     <content styleCode="bold">Who should not take WYMZYA Fe?</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Do not take WYMZYA Fe if you:</content>
                  </paragraph>
                  <list listType="unordered" ID="ID852" styleCode="Disc">
                     <item>smoke and are over 35 years of age</item>
                     <item>had blood clots in your arms, legs, lungs, or eyes</item>
                     <item>had a problem with your blood that makes it clot more than normal</item>
                     <item>have certain heart valve problems or irregular heart beat that      increases your risk of having blood clots</item>
                     <item>had a stroke</item>
                     <item>had a heart attack</item>
                     <item>have high blood pressure that cannot be controlled by medicine</item>
                     <item>have diabetes with kidney, eye, nerve, or blood vessel damage</item>
                     <item>have certain kinds of severe migraine headaches with aura, numbness,      weakness or changes in vision, or any migraine headaches if you are over      35 years of age</item>
                     <item>have liver problems, including liver tumors</item>
                     <item>have any unexplained vaginal bleeding</item>
                     <item>are pregnant</item>
                     <item>had breast cancer or any cancer that is sensitive to female hormones</item>
                     <item>Take any Hepatitis C drug combination containing      ombitasvir/paritaprevir/ritonavir, with or without dasabuvir. This may      increase levels of the liver enzyme "alanine aminotransferase" (ALT)      in the blood.</item>
                  </list>
                  <paragraph ID="ID853">
                     <content styleCode="bold">If any of these conditions happen while you are taking WYMZYA Fe , stop taking WYMZYA Fe right away and talk to your healthcare provider. Use non-hormonal contraception when you stop taking WYMZYA Fe.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">What should I tell my healthcare provider before taking WYMZYA Fe?</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Tell your healthcare provider if you:</content>
                  </paragraph>
                  <list listType="unordered" ID="ID855" styleCode="Disc">
                     <item>are pregnant or think you may be pregnant</item>
                     <item>are depressed now or have been depressed in the past</item>
                     <item>had yellowing of your skin or eyes (jaundice) caused by pregnancy      (cholestasis of pregnancy)</item>
                     <item>are breastfeeding or plan to breastfeed. WYMZYA Fe may decrease the amount      of breast milk you make. A small amount of the hormones in WYMZYA Fe may      pass into your breast milk. Talk to your healthcare provider about the      best birth control method for you while breastfeeding.</item>
                  </list>
                  <paragraph ID="ID856">
                     <content styleCode="bold">Tell your healthcare provider about all the medicines you take</content>, including prescription and over-the-counter medicines, vitamins and herbal supplements.</paragraph>
                  <paragraph>WYMZYA Fe may affect the way other medicines work, and other medicines may affect how well WYMZYA Fe works.</paragraph>
                  <paragraph>Know the medicines you take. Keep a list of them to show your healthcare provider and pharmacist when you get a new medicine.</paragraph>
                  <paragraph>
                     <content styleCode="bold">How do I take WYMZYA Fe?</content>
                  </paragraph>
                  <paragraph>Read the <content styleCode="bold">Instructions for Use</content> at the end of this Patient Information.</paragraph>
                  <paragraph>
                     <content styleCode="bold">What are the possible serious side effects of WYMZYA Fe?</content>
                  </paragraph>
                  <list listType="unordered" ID="ID857" styleCode="Disc">
                     <item>
                        <content styleCode="bold">Like pregnancy, WYMZYA Fe may cause serious side effects,      including blood clots in your lungs, heart attack, or a stroke that may      lead to death</content> . Some other examples of serious blood clots include      blood clots in the legs or eyes.</item>
                  </list>
                  <paragraph ID="ID858">Serious blood clots can happen especially if you smoke, are obese, or are older than 35 years of age. Serious blood clots are more likely to happen when you:</paragraph>
                  <list listType="unordered" ID="ID859" styleCode="Disc">
                     <item>first start taking birth control pills</item>
                     <item>restart the same or different birth control pills after not using      them for a month or more</item>
                  </list>
                  <paragraph ID="ID860">
                     <content styleCode="bold">Call your healthcare provider or go to a hospital emergency room right away if you have:</content>
                  </paragraph>
                  <list listType="unordered" ID="ID861" styleCode="Disc">
                     <item>leg pain      that will not go away</item>
                     <item>sudden      severe shortness of breath</item>
                     <item>sudden      change in vision or blindness</item>
                     <item>chest pain</item>
                     <item>a sudden,      severe headache unlike your usual headaches</item>
                     <item>weakness or      numbness in your arm or leg</item>
                     <item>trouble      speaking</item>
                  </list>
                  <paragraph ID="ID862">
                     <content styleCode="bold">Other serious side effects include:</content>
                  </paragraph>
                  <list listType="unordered" ID="ID863" styleCode="Disc">
                     <item>
                        <content styleCode="bold">liver problems, including:</content>
                        <list listType="unordered" styleCode="Circle">
                           <item>rare liver tumors</item>
                           <item>jaundice (cholestasis), especially if you previously had cholestasis of pregnancy. Call your healthcare provider if you have yellowing of your skin or eyes.</item>
                        </list>
                     </item>
                     <item>
                        <content styleCode="bold">high blood pressure</content> . You should see your healthcare provider for a yearly check of your blood pressure.</item>
                     <item>
                        <content styleCode="bold">gallbladder problems</content>
                     </item>
                     <item>
                        <content styleCode="bold">changes in the sugar and fat (cholesterol and triglycerides) levels in your blood</content>
                     </item>
                     <item>
                        <content styleCode="bold">new or worsening headaches including migraine headaches</content>
                     </item>
                     <item>
                        <content styleCode="bold">depression</content>
                     </item>
                     <item>
                        <content styleCode="bold">possible cancer in your breast and cervix</content>
                     </item>
                     <item>
                        <content styleCode="bold">swelling of your skin especially around your mouth, eyes, and in your throat (angioedema)</content> . Call your healthcare provider if you have a swollen face, lips, mouth tongue or throat, which may lead to difficulty swallowing or breathing. Your chance of having angioedema is higher if you have a history of angioedema.</item>
                     <item>
                        <content styleCode="bold">dark patches of skin around your forehead, nose, cheeks and around your mouth, especially during pregnancy (chloasma).</content> Women who tend to get chloasma should avoid spending a long time in sunlight, tanning booths, and under sun lamps while taking WYMZYA Fe. Use sunscreen if you have to be in the sunlight.</item>
                  </list>
                  <paragraph ID="ID864">
                     <content styleCode="bold">What are the most common side effects of WYMZYA Fe?</content>
                  </paragraph>
                  <paragraph>The most common side effects of WYMZYA Fe include:</paragraph>
                  <list listType="unordered" ID="ID865" styleCode="Disc">
                     <item>headache (including migraine)</item>
                     <item>nausea and vomiting</item>
                     <item>breast problems<list listType="unordered" styleCode="Circle">
                           <item>tenderness, pain and discomfort</item>
                           <item>enlargement and swelling</item>
                           <item>discharge</item>
                           <item>nipple pain</item>
                        </list>
                     </item>
                     <item>belly pain</item>
                     <item>pain with your periods (menstrual cycle)</item>
                     <item>mood changes, including depression</item>
                     <item>acne</item>
                     <item>vaginal infections</item>
                     <item>bloating</item>
                     <item>weight gain</item>
                  </list>
                  <paragraph ID="ID866">These are not all the possible side effects of WYMZYA Fe . For more information, ask your healthcare provider or pharmacist.</paragraph>
                  <paragraph>You may report side effects to the FDA at 1-800-FDA-1088.</paragraph>
                  <paragraph>
                     <content styleCode="bold">What else should I know about taking WYMZYA Fe?</content>
                  </paragraph>
                  <list listType="unordered" ID="ID867" styleCode="Disc">
                     <item>If you are scheduled for any lab tests, tell your healthcare      provider you are taking WYMZYA Fe. Certain blood tests may be affected by      WYMZYA Fe.</item>
                     <item>WYMZYA Fe does not protect against HIV infection (AIDS) and other      sexually transmitted infections.</item>
                  </list>
                  <paragraph ID="ID868">
                     <content styleCode="bold">How should I store WYMZYA Fe?</content>
                  </paragraph>
                  <list listType="unordered" ID="ID869" styleCode="Disc">
                     <item>Store WYMZYA Fe at room temperature between 68°F to 77°F (20°C      to 25°C).</item>
                     <item>Keep WYMZYA Fe and all medicines out of the reach of children.</item>
                     <item>Store away from light.</item>
                  </list>
                  <paragraph ID="ID870">
                     <content styleCode="bold">General information about the safe and effective use of WYMZYA Fe.</content>
                  </paragraph>
                  <paragraph>Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use WYMZYA Fe for a condition for which it was not prescribed. Do not give WYMZYA Fe to other people.</paragraph>
                  <paragraph>This Patient Information summarizes the most important information about WYMZYA Fe. You can ask your pharmacist or healthcare provider for information about WYMZYA Fe that is written for health professionals.</paragraph>
                  <paragraph>For more information, call Lupin Pharmaceuticals, Inc. at 1-800-399-2561.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Does hormonal birth control cause cancer?</content>
                  </paragraph>
                  <paragraph>It is not known if hormonal birth control pills causes breast cancer. Some studies, but not all, suggest that there could be a slight increase in the risk of breast cancer among current users with longer duration of use. </paragraph>
                  <paragraph>If you have breast cancer now, or have had it in the past, do not use hormonal birth control because some breast cancers are sensitive to hormones. </paragraph>
                  <paragraph>Women who use birth control pills may have a slightly higher chance of getting cervical cancer. However, this may be due to other reasons such as having more sexual partners.</paragraph>
                  <paragraph>
                     <content styleCode="bold">What if I want to become pregnant?</content>
                  </paragraph>
                  <paragraph>You may stop taking the pill whenever you wish. Consider a visit with your healthcare provider for a pre-pregnancy checkup before you stop taking the pill.</paragraph>
                  <paragraph>
                     <content styleCode="bold">What should I know about my period when taking WYMZYA Fe?</content>
                  </paragraph>
                  <paragraph>Your periods may be lighter and shorter than usual. Some women may miss a period. Irregular vaginal bleeding or spotting may happen while you are taking WYMZYA Fe, especially during the first few months of use. This usually is not a serious problem. It is important to continue taking your pills on a regular schedule to prevent a pregnancy.</paragraph>
                  <paragraph>
                     <content styleCode="bold">What are the ingredients in WYMZYA Fe?</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Active ingredients:</content>
                  </paragraph>
                  <paragraph>White pills: norethindrone and ethinyl estradiol</paragraph>
                  <paragraph>Brown pills: ferrous fumarate</paragraph>
                  <paragraph>
                     <content styleCode="bold">Inactive ingredients:</content>
                  </paragraph>
                  <paragraph>White pills: lactose anhydrous, magnesium stearate, mannitol, microcrystalline cellulose, povidone, sodium starch glycolate, sucralose, vanillin and vitamin E.</paragraph>
                  <paragraph>Brown pills: magnesium stearate, microcrystalline cellulose, povidone, sodium starch glycolate and sucrose.</paragraph>
                  <paragraph ID="ID871">
                     <content styleCode="bold">Instructions For Use</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">WYMZYA<sup>TM</sup> Fe</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">[WYM-zee-yah EFF-EE]</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">[norethindrone and ethinyl estradiol tablets (chewable) and ferrous fumarate tablets]</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Important Information about taking WYMZYA Fe </content>
                  </paragraph>
                  <list listType="unordered" ID="ID872" styleCode="Disc">
                     <item>Take <content styleCode="bold">1</content> pill every day at the same time. Take the pills in the order directed on your replace.</item>
                     <item>Both the white pills and the brown pills may be swallowed whole or chewed and swallowed. <content styleCode="bold">If the pill is chewed, drink a full glass (8 ounces) of liquid immediately after swallowing.</content>
                     </item>
                     <item>Do not skip your pills, even if you do not have sex often. If you miss pills (including starting the pack late) <content styleCode="bold">you could get pregnant</content> . The more pills you miss, the more likely you are to get pregnant.</item>
                     <item>If you have trouble remembering to take WYMZYA Fe, talk to your healthcare provider. When you first start taking WYMZYA Fe, spotting or light bleeding in between your periods may occur. Contact your healthcare provider if this does not go away after a few months.</item>
                     <item>You may feel sick to your stomach (nauseous), especially during the first few months of taking WYMZYA Fe. If you feel sick to your stomach, do not stop taking the pill. The problem will usually go away. If your nausea does not go away, call your healthcare provider.</item>
                     <item>Missing pills can also cause spotting or light bleeding, even when you take the missed pills later. On the days you take 2 pills to make up for missed pills (see below), you could also feel a little sick to your stomach.</item>
                     <item>It is not uncommon to miss a period. However, if you miss a period and have not taken WYMZYA Fe according to directions, or miss <content styleCode="bold">2</content> periods in a row, or feel like you may be pregnant, call your healthcare provider. If you have a positive pregnancy test, you should stop taking WYMZYA Fe.</item>
                     <item>If you have vomiting or diarrhea within <content styleCode="bold">3 to 4</content> hours of taking your pill, take another pill of the same color from your extra replace. If you do not have an extra replace, take the next pill in your replace. Continue taking all your remaining pills in order. Start the first pill of your next replace the day after finishing your current replace. This will be 1 day earlier than originally scheduled. Continue on your new schedule.</item>
                     <item>If you have vomiting or diarrhea for more than 1 day, your birth control pills may not work as well. Use an additional birth control method, like condoms and a spermicide, until you check with your healthcare provider.</item>
                     <item>Stop taking WYMZYA Fe at least <content styleCode="bold">4</content> weeks before you have major surgery and do not restart after the surgery without asking your healthcare provider. Be sure to use other forms of contraception (like condoms and spermicide) during this time period.</item>
                  </list>
                  <paragraph ID="ID873">
                     <content styleCode="bold">Before you start taking WYMZYA Fe:</content>
                  </paragraph>
                  <list listType="unordered" ID="ID874" styleCode="Disc">
                     <item>Decide what time of day you want to take your pill. It is important to take it at the same time every day and in the order as directed on your blister.</item>
                     <item>Have backup contraception (condoms and spermicide) available and if possible, an extra full pack of pills as needed.</item>
                  </list>
                  <paragraph ID="ID875">
                     <content styleCode="bold">When should I start taking WYMZYA Fe?</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">If you start taking WYMZYA Fe and you have not used a hormonal birth control method before:</content>
                  </paragraph>
                  <list listType="unordered" ID="ID876" styleCode="Disc">
                     <item>There are 2      ways to start taking your birth control pills. You can either start on a      Sunday (Sunday Start) or on the first day (Day 1) of your natural      menstrual period (Day 1 Start). Your healthcare provider should tell you      when to start taking your birth control pill.</item>
                     <item>If you use      the Sunday Start, use non-hormonal back-up contraception such as condoms      and spermicide for the first <content styleCode="bold">7</content> days that you take WYMZYA Fe. You do      not need back-up contraception if you use the Day 1 Start.</item>
                  </list>
                  <paragraph ID="ID877">
                     <content styleCode="bold">If you start taking WYMZYA Fe and you are switching from another birth control pill:</content>
                  </paragraph>
                  <list listType="unordered" ID="ID878" styleCode="Disc">
                     <item>Start your new WYMZYA Fe pack on the same day that you would start      the next pack of your previous birth control method.</item>
                     <item>Do not continue taking the pills from your previous birth control      pack.</item>
                  </list>
                  <paragraph ID="ID879">
                     <content styleCode="bold">If you start taking WYMZYA Fe and previously used a vaginal ring or transdermal patch:</content>
                  </paragraph>
                  <list listType="unordered" ID="ID880" styleCode="Disc">
                     <item>Start using WYMZYA Fe on the day you would have reapplied the next      ring or patch.</item>
                  </list>
                  <paragraph ID="ID881">
                     <content styleCode="bold">If you start taking WYMZYA Fe and you are switching from a progestin-only method such as an implant or injection:</content>
                  </paragraph>
                  <list listType="unordered" ID="ID882" styleCode="Disc">
                     <item>Start taking WYMZYA Fe on the day of removal of your implant or on      the day when you would have had your next injection.</item>
                  </list>
                  <paragraph ID="ID883">
                     <content styleCode="bold">If you start taking WYMZYA Fe and you are switching from an intrauterine device or system (IUD or IUS):</content>
                  </paragraph>
                  <list listType="unordered" ID="ID884" styleCode="Disc">
                     <item>Start taking WYMZYA Fe on the day of removal of your IUD or IUS.</item>
                     <item>You do not need back-up contraception if your IUD or IUS is removed      on the first day (Day 1) of your period. If your IUD or IUS is removed on      any other day, use non-hormonal back-up contraception such as condoms and      spermicide for the first <content styleCode="bold">7</content> days that you take WYMZYA Fe.</item>
                  </list>
                  <paragraph ID="ID885">
                     <content styleCode="bold">Keep a calendar to track your period:</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">If this is the first time</content> you are taking birth control pills, read, "<content styleCode="bold">When should I start taking WYMZYA Fe</content>?" above. Follow these instructions for either a <content styleCode="bold">Sunday Start</content> or a <content styleCode="bold">Day 1 Start</content>.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Sunday Start:</content>
                  </paragraph>
                  <paragraph>You will use a <content styleCode="bold">Sunday Start</content> if your healthcare provider told you to take your first pill on a Sunday.</paragraph>
                  <list listType="unordered" ID="ID886" styleCode="Disc">
                     <item>Take pill <content styleCode="bold">1</content> on the Sunday <content styleCode="bold">after your period starts</content> .</item>
                     <item>If your period starts on a Sunday, take pill "<content styleCode="bold">1</content> " that day and refer to Day 1 Start instructions below.</item>
                     <item>Take <content styleCode="bold">1</content> pill every day in the order on the blister at the same time each day for <content styleCode="bold">28</content> days.</item>
                     <item>After taking the last pill on <content styleCode="bold">Day 28</content> from the blister, start taking the first pill from a new pack, on the same day of the week as the first pack (Sunday). Take the first pill in the new pack whether or not you are having your period.</item>
                     <item>Use non-hormonal back-up contraception such as condoms and spermicide for the first <content styleCode="bold">7</content> days of the first cycle that you take WYMZYA Fe.</item>
                  </list>
                  <paragraph ID="ID887">
                     <content styleCode="bold">Day 1 Start:</content>
                  </paragraph>
                  <paragraph>You will use a <content styleCode="bold">Day 1 Start</content> if your doctor told you to take your first pill (Day 1) on the <content styleCode="bold">first day of your period</content>.</paragraph>
                  <list listType="unordered" ID="ID888" styleCode="Disc">
                     <item>Take <content styleCode="bold">1</content> pill every day in the order of the blister, at the same time each day, for <content styleCode="bold">28</content> days.</item>
                     <item>After taking the last pill on <content styleCode="bold">Day 28</content> from the blister, start taking the first pill from a new pack, on the same day of the week as the first pack. Take the first pill in the new pack whether or not you are having your period.</item>
                  </list>
                  <paragraph ID="ID889">
                     <content styleCode="bold">Instructions for using your blister (pill pack):</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Step 1.</content>
                  </paragraph>
                  <paragraph>Look at your WYMZYA Fe pill pack. <content styleCode="bold">See Figure A.</content>
                  </paragraph>
                  <paragraph>The WYMZYA Fe pill pack has:</paragraph>
                  <list listType="unordered" ID="ID890" styleCode="Disc">
                     <item>
                        <content styleCode="bold">21</content> white (active) pills with hormone for <content styleCode="bold">Week 1 through Week 3</content> .</item>
                     <item>
                        <content styleCode="bold">7</content> brown (inactive) pills without hormones for <content styleCode="bold">Week 4</content> .</item>
                  </list>
                  <renderMultiMedia referencedObject="MM5"/>
                  <paragraph ID="ID892">
                     <content styleCode="bold">Step 2.</content>
                  </paragraph>
                  <paragraph>Find:</paragraph>
                  <list listType="unordered" ID="ID893" styleCode="Disc">
                     <item>where on your pack to start taking pills</item>
                     <item>in what order to take your pills (follow the arrows)</item>
                     <item>the week numbers</item>
                  </list>
                  <paragraph ID="ID894">
                     <content styleCode="bold">Step 3.</content>
                  </paragraph>
                  <paragraph>Remove the white pill by pressing the pill through the foil in the bottom of the pill pack. Continue taking the white pills for 21 days.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Step 4.</content>
                  </paragraph>
                  <paragraph>On the first day of <content styleCode="bold">Week 4</content> start taking the brown pills. Take the brown pill for <content styleCode="bold">7 days</content>.Your period should start during this time.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Step 5.</content>
                  </paragraph>
                  <paragraph>When you have taken all of the brown pills in your pill pack, get a new pill pack and start taking the white pills.</paragraph>
                  <list listType="unordered" ID="ID895" styleCode="Disc">
                     <item>
                        <content styleCode="bold">For a Day 1 start:</content>
                     </item>
                  </list>
                  <paragraph ID="ID896">Begin your next pill pack on the same day of the week as your first cycle pill pack.</paragraph>
                  <list listType="unordered" ID="ID897" styleCode="Disc">
                     <item>
                        <content styleCode="bold">For a Sunday Start:</content>
                     </item>
                  </list>
                  <paragraph ID="ID898">Begin your next pill pack on Sunday.</paragraph>
                  <paragraph>
                     <content styleCode="bold">What should I do if I miss any WYMZYA Fe pills?</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">If you miss 1 pill in Weeks 1, 2, or 3, follow these steps:</content>
                  </paragraph>
                  <list listType="unordered" ID="ID899" styleCode="Disc">
                     <item>Take it as soon as you remember. Take the next pill at your regular      time. This means you may take <content styleCode="bold">2</content> pills in <content styleCode="bold">1</content> day.</item>
                     <item>Then continue taking <content styleCode="bold">1</content> pill every day until you finish the      pack.</item>
                     <item>You do not need to use a back-up birth control method if you have      sex.</item>
                  </list>
                  <paragraph ID="ID900">
                     <content styleCode="bold">If you miss 2 pills in Week 1 or Week 2 of your pack, follow these steps:</content>
                  </paragraph>
                  <list listType="unordered" ID="ID901" styleCode="Disc">
                     <item>Take the 2 missed pills as soon as possible and the next 2 pills the      next day.</item>
                     <item>Then continue to take<content styleCode="bold">1</content> pill every day until you finish the      pack.</item>
                     <item>Use a non-hormonal birth control method (such as a condom and      spermicide) as a back-up if you have sex during the first <content styleCode="bold">7 days</content> after missing your pills.</item>
                  </list>
                  <paragraph ID="ID902">
                     <content styleCode="bold">If you miss 2 pills in a row in Week 3, or you miss 3 or more pills in a row during Weeks 1, 2, or 3 of the pack, follow these steps:</content>
                  </paragraph>
                  <list listType="unordered" ID="ID903" styleCode="Disc">
                     <item>
                        <content styleCode="bold">If you are a Day 1 Starter:</content>
                        <list listType="unordered" styleCode="Circle">
                           <item>Throw out the rest of the pill pack and start a new pack that same day.</item>
                        </list>
                     </item>
                     <item>
                        <content styleCode="bold">If you are a Sunday Starter:</content>
                        <list listType="unordered" styleCode="Circle">
                           <item>Keep taking <content styleCode="bold">1</content> pill every day until Sunday. On Sunday, throw out the rest of the pack and start a new pack of pills that same day.</item>
                        </list>
                     </item>
                     <item>You may not have your period this month but this is expected. However, if you miss your period 2 months in a row, call your healthcare provider because you might be pregnant.</item>
                     <item>You could become pregnant if you have sex during the first 7 days after you restart your pills. You MUST use a non-hormonal birth control method (such as a condom and spermicide) as a back-up if you have sex during the first 7 days after you restart your pills.</item>
                  </list>
                  <paragraph ID="ID904">
                     <content styleCode="bold">If you have any questions or are unsure about the information in this leaflet, call your healthcare provider.</content>
                  </paragraph>
                  <paragraph>This Patient Information and Instructions for Use has been approved by the U.S. Food and Drug Administration.</paragraph>
                  <paragraph>WYMZYA™ Fe is a trademark of Lupin Pharmaceuticals, Inc.</paragraph>
                  <renderMultiMedia referencedObject="MM6"/>
                  <paragraph ID="ID933">Distributed by:</paragraph>
                  <paragraph>
                     <content styleCode="bold">Lupin Pharmaceuticals, Inc.</content>
                  </paragraph>
                  <paragraph>Naples, FL 34108</paragraph>
                  <paragraph>United States</paragraph>
                  <paragraph>Manufactured by:</paragraph>
                  <paragraph>
                     <content styleCode="bold">Lupin Limited</content>
                  </paragraph>
                  <paragraph>Pithampur (M.P.) - 454 775</paragraph>
                  <paragraph>India</paragraph>
                  <paragraph>Revised: November 2024                                                                               ID#: 277223</paragraph>
               </text>
               <effectiveTime value="20250514"/>
               <component>
                  <observationMedia ID="MM4">
                     <text>image-2</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="519db8a9-48ab-4826-a2b3-6d67d6a24017-04.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM5">
                     <text>image-3</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="519db8a9-48ab-4826-a2b3-6d67d6a24017-05.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM6">
                     <text>image</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="519db8a9-48ab-4826-a2b3-6d67d6a24017-06.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID905">
               <id root="36f92505-5b44-4371-aefc-bf3b6b65c304"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <text>
                  <paragraph ID="ID906">WYMZYA<content styleCode="bold">
                        <sup>TM</sup>
                     </content> Fe [norethindrone and ethinyl estradiol tablets USP (chewable), 0.4 mg/0.035 mg and ferrous fumarate tablets, 75 mg]</paragraph>
                  <paragraph>Rx only</paragraph>
                  <paragraph>NDC 68180-873-71</paragraph>
                  <paragraph>Blister Label: 28 Tablets</paragraph>
                  <renderMultiMedia referencedObject="MM7"/>
                  <paragraph ID="ID908">WYMZYA<content styleCode="bold">
                        <sup>TM</sup>
                     </content> Fe [norethindrone and ethinyl estradiol tablets USP (chewable), 0.4 mg/0.035 mg and ferrous fumarate tablets, 75 mg]</paragraph>
                  <paragraph>Rx only</paragraph>
                  <paragraph>NDC 68180-873-71</paragraph>
                  <paragraph>Pouch Label: 1 blister of 28 Tablets</paragraph>
                  <renderMultiMedia referencedObject="MM8"/>
                  <paragraph ID="ID910">WYMZYA<content styleCode="bold">
                        <sup>TM</sup>
                     </content> Fe [norethindrone and ethinyl estradiol tablets USP (chewable), 0.4 mg/0.035 mg and ferrous fumarate tablets, 75 mg]</paragraph>
                  <paragraph>Rx only</paragraph>
                  <paragraph>NDC 68180-873-73</paragraph>
                  <paragraph>Carton Label: 3 blisters of 28 Tablets</paragraph>
                  <renderMultiMedia referencedObject="MM9"/>
               </text>
               <effectiveTime value="20250514"/>
               <component>
                  <observationMedia ID="MM7">
                     <text>image-4</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="519db8a9-48ab-4826-a2b3-6d67d6a24017-07.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM8">
                     <text>image-5</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="519db8a9-48ab-4826-a2b3-6d67d6a24017-08.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM9">
                     <text>image-6</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="519db8a9-48ab-4826-a2b3-6d67d6a24017-09.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>